Management reiterated expectations to generate initial revenue from the percutaneous electrode in the second half of the year, noting, “This initial revenue recognition will value based on the ...
HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed ...
Nanosecond PFA Cardiac Surgical System for ablation of cardiac tissue to be highlighted in presentation and poster sessions. “We believe the Nanosecond PFA Cardiac Surgical System has the potential to ...
Pulse Biosciences, Inc. recently announced that late-breaking 6- and 12-month data from its first-in-human European feasibility study of the nPulse Cardiac Catheter Ablation System have been accepted ...
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced ...
Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s ...
An update from Pulse Biosciences ( (PLSE)) is now available. On December 9, 2025, Pulse Biosciences, Inc. conducted its 2025 Annual Meeting of Stockholders virtually. During the meeting, stockholders ...
Clinical Data on Benign Thyroid Nodule Ablation to be highlighted in presentation “We believe the differentiated nPulse Vybrance Percutaneous Electrode system is setting a new standard for safety, ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results